Global health sciences venture fund
VC Fund
Vancouver, Canada
Global health sciences venture fund is a VC fund in Vancouver focused on Biotechnology and Health Care. The strength of the life science industry here and the quality of its technologies. We anticipate that internationally competitive Canadian companies will do well having a fund of this size and calibre at their doorstep, and we believe such a fund will energize the sector and be a magnet for further capital."
- Total investments:
- 13
- Last investment:
- Lead investor:
- 31%
- Fund size:
- $500M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Global health sciences venture fund invests in
Stages Global health sciences venture fund invests in
Countries Global health sciences venture fund invests in
Round sizes
Round size
- Series A
- $10M–$19M
- Series B
- $23M–$30M
- Series C
- $20M–$72M
Investment Focus
Industry
- Biotechnology 8 (62%)
- Health Care 7 (54%)
- Therapeutics 6 (46%)
- Life Science 4 (31%)
- Medical 3 (23%)
Stage
- Series C 4 (31%)
- Series A 3 (23%)
- Series B 2 (15%)
- Funding Round 2 (15%)
- Seed 1 (8%)
Country
- United States 7 (54%)
- Canada 2 (15%)
- Spain 1 (8%)
- France 1 (8%)
- Israel 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Based on clinical whole genome sequencing (WGS) and using a single patient sample, Variantyx's Genomic Unity® test identifies and reports all major variant types including small sequence changes, structural variants, mitochondrial variants and short tandem repeat expansions. This comprehensive test test eliminates the need for traditionalstep-wise, reiterative genetic testing. | $20M / Series C / Mar 15, 2021 | ||
| EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema.EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer TechnologyIncubator. | $25M / Series C / Mar 15, 2021 | ||
| CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $21M / Series D / Mar 11, 2021 | ||
| ARTMS is a developer of technology that transforms the production of diagnostic imaging isotopes. Artms provides the QUANTM Irradiation SystemTM (QISTM), which enables decentralized, and local production of important medical isotopes including gallium-68 (68Ga), zirconium-89 (89Zr), technetium‐99m (99mTc) and copper-64 (64Cu). | $19M / Series A / May 20, 2020 | ||
| Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with a high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins,which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. | $56M / Series C / Mar 04, 2020 | ||
| EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will targetimproving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). | $10M / Series A / Feb 19, 2020 | ||
| Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers by exploiting unique insights into chromosomal instability | $12M / Seed / Feb 11, 2020 | ||
| Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasiveprocedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability.They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures. | $30M / Series B / Jan 08, 2020 | ||
| Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with a high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins,which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. | $23M / Series B / Jan 08, 2019 | ||
| SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cellengineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges. | $72M / Series C / Aug 08, 2018 | ||
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Global health sciences venture fund invest in?
Global health sciences venture fund invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series C and Series A stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Global health sciences venture fund invest in?
Global health sciences venture fund typically joins rounds of $10M–$19M at Series A, $23M–$30M at Series B and $20M–$72M at Series C. These are whole funding-round sizes, not Global health sciences venture fund's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Global health sciences venture fund took part in.
When did Global health sciences venture fund last invest?
The most recent investment recorded for Global health sciences venture fund closed in Mar 2021. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
